106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2018 All rights reserved
ASCONCPC1833b
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncology
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
genitourinary-cancer-guidelines. Copyright © 2018 by American Society of Clinical Oncology.
All rights reserved.
Abbreviations
AAP, abiraterone with prednisone or prednisolone; ADT, androgen deprivation therapy;
CHAARTED, Chemohormonal Androgen Ablation Randomized Trial; LATITUDE,
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation
erapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk,
Metastatic Hormone-Naive Prostate Cancer (mHNPC); mCRPC, metastatic castration-resistant
prostate cancer; STAMPEDE, Systemic erapy in Advancing or Metastatic Prostate Cancer:
Evaluation of Drug Efficacy
Source
Morris MJ et al. Optimizing anti-cancer therapy in metastatic non-castrate prostate cancer:
American Society of Clinical Oncolog y Clinical Practice Guideline. J Clin Oncol. 2018 April 2;
doi: 10.1200/JCO.2018.78.0619. [Epub ahead of print]
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets,
frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/genitourinary-cancer-guidelines
Recommendation Grading
Type Evidence Quality
Strength of
Recommendation
EB Evidence-based H High Strong
I Intermediate Moderate
IC
Informal Consensus L Low Weak
Ins Insufficient
